AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Marinomed Biotech AG

Declaration of Voting Results & Voting Rights Announcements Dec 31, 2024

749_dva_2024-12-31_c1263f0f-5ffb-4e7a-8104-991262ee4886.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

News Details

Voting Rights Announcements | 30 December 2024 14:08

Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

Marinomed Biotech AG

Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

30.12.2024 / 14:08 CET/CEST

Dissemination of a Voting Rights Announcement transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Major holdings notification pursuant to Sec. 130 to 134 BörseG 2018

Wien,  30.12.2024

Overview

Notification made after deadline

Caution: In case of violations of major holdings notification rules, please pay attention to Section 137 BörseG 2018 (Suspension of voting rights)

1. Issuer: Marinomed Biotech AG

2. Reason for the notification: Event changing the breakdown of voting rights

3. Person subject to notification obligation

Name: Erste Asset Management GmbH

City: 1100 Wien, Am Belvedere 1

Country: Österreich

4. Name of shareholder(s):

5. Date on which the threshold was crossed or reached: 27.12.2024

6. Total positions

% of voting rights attached to shares (7.A) % of voting rights through financial/other instruments (7.B.1 + 7.B.2) Total of both in % (7.A + 7.B) Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached 9,56 % 0,00 % 9,56 % 1 778 333
Position of previous notification (if applicable) 10,32 % 10,32 %

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares
ISIN Code Number of voting rights % of voting rights
Direct

(Sec 130 BörseG 2018)
Indirect

(Sec 133 BörseG 2018)
Direct

(Sec 130 BörseG 2018)
Indirect

(Sec 133 BörseG

2018)
ATMARINOMED6 170 027 9,56 %
SUBTOTAL A 170 027 9,56 %
B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG 2018
Type of instrument Expiration Date Exercise Period Number of voting

rights that may be

acquired if the

instrument is exercised
% of voting rights
SUBTOTAL B.1
B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG 2018
Type of instrument Expiration Date Exercise Period Physical /

Cash Settlement
Number of

voting rights
% of voting rights
SUBTOTAL B.2

8. Information in relation to the person subject to the notification obligation:

☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☐ Full chain of controlled undertakings through which the voting rights and/or the financial/other instruments are effectively held starting with the ultimate controlling natural person or legal entity:

9. In case of proxy voting

Date of general meeting: –

Voting rights after general meeting: – is equivalent to – voting rights.

10. Sonstige Kommentare:

Die gemeldeten Stimmrechtsanteile der Erste Asset Management GmbH werden nicht direkt, sondern von den Investmentfonds gehalten, die von der Erste Asset Management GmbH (einschließlich ihrer Zweigniederlassungen in Tschechien und Slowakei) als Verwaltungsgesellschaft verwaltet werden. Es handelt sich daher nicht um Beteiligungen der Verwaltungsgesellschaft an der Marinomed Biotech AG.

Wien am  30.12.2024


30.12.2024 CET/CEST


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Internet: www.marinomed.com
End of News EQS News Service

show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.